Cognitive behavioral therapy (CBT) should be the first line of treatment in younger patients with major depressive disorder before clinicians prescribe medication...
A digital therapeutic launched by Pear Therapeutics and Novartis’ generics and biosimilars division Sandoz has become the first FDA-approved app of its kind for use in the treatment of opioid use disorder (OUD), it has emerged.
Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554), today announced its commitment to CBT Pharmaceuticals as a leader in the discovery and development of cancer combination therapies.